Evidence map›Paper›PMID 36551480›Full record

ArticleAntibiotics (Basel, Switzerland)2022

T2Bacteria and T2Resistance Assays in Critically Ill Patients with Sepsis or Septic Shock: A Descriptive Experience.

Daniele Roberto Giacobbe, Francesca Crea, Paola Morici, Laura Magnasco, Vincenzo Di Pilato, Federica Briano, Edward Willison, Rachele Pincino, Silvia Dettori, Stefania Tutino and 13 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Diagnostic stewardship in sepsis: minding the gap from the microbiology lab to ward.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Daniele Roberto GiacobbeDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0003-2385-1759
Francesca CreaMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Paola MoriciMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.ORCID 0000-0003-4822-3601
Laura MagnascoInfectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.ORCID 0000-0002-6343-3271
Vincenzo Di PilatoDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-5863-5805
Federica BrianoDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
Edward WillisonMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Rachele PincinoDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
Silvia DettoriDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
Stefania TutinoDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
Simone EspositoMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Erika CoppoMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Chiara DentoneInfectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Federica PortunatoInfectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Malgorzata MikulskaDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-5535-4602
Chiara RobbaDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.
Antonio VenaDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-0697-3992
Denise BattagliniAnesthesia and Intensive Care, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.ORCID 0000-0002-6895-6442
Iole BrunettiAnesthesia and Intensive Care, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Lorenzo BallDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.
Paolo PelosiDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy.
Anna MarcheseMicrobiology Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Matteo BassettiDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.
Ospedale Policlinico San Martino · ITOspedale di Sanremo · ITOspedale San Paolo · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of rapid molecular tests may anticipate the identification of causative agents and resistance determinants in the blood of critically ill patients with sepsis. From April to December 2021, all intensive care unit patients with sepsis or septic shock who were tested with the T2Bacteria and T2Resistance assays were included in a retrospective, single center study. The primary descriptive endpoints were results of rapid molecular tests and concomitant blood cultures. Overall, 38 combinations of T2Bacteria and T2Resistance tests were performed. One or more causative agent(s) were identified by the T2Bacteria assay in 26% of episodes (10/38), whereas negative and invalid results were obtained in 66% (25/38) and 8% (3/38) of episodes, respectively. The same pathogen detected by the T2Bacteria test grew from blood cultures in 30% of cases (3/10). One or more determinant(s) of resistance were identified by the T2Resistance assay in 11% of episodes (4/38). Changes in therapy based on T2Bacteria and/or T2Resistance results occurred in 21% of episodes (8/38). In conclusion, T2Bacteria/T2Resistance results can influence early treatment decisions in critically ill patients with sepsis or septic shock in real-life practice. Large, controlled studies remain necessary to confirm a favorable impact on patients' outcomes and antimicrobial stewardship interventions.

Indexed as

antimicrobial resistanceBSIdiagnosisrapid testssepsisseptic shockT2

Identifiers

PMID36551480
PMCPMC9774778
OpenAlexW4312140506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.